Wednesday, March 24, 2010

NIMH Director on Industry Influence over Psychiatry

The current JAMA (subscription required) features a commentary by Dr. Thomas R. Insel, Director of the National Institutes of Mental Health, on the problem of Pharma influence over psychiatry. Our blogging friends have quite different takes on the matter.

To Barney Carroll--
--Dr. Insel has participated in a whitewash, spending most of the commentary making excuses that psychiatrists are at the pharmaceutical industry trough about the same amount as the pigs from other medical specialties, so it is unfair to single them out. Dr. Carroll opines that this whitewash may be motivated by Dr. Insel's close ties with Dr. Charles Nemeroff, whose escapades we have detailed on numerous occasions and is basically the poster child for academic psychiatrists eagerly doing the bidding of industry. Dr. Insel alludes elliptically to "the resignation of a chair of a prestigious psychiatry department" as one of the "major effects" produced by heightened publicity around conflicts of interest in his field. (Nemeroff, as we have covered, resigned as chair at Emory but soon after was hired on as chair by Miami.)

To Danny Carlat--
--it is much more significant that Dr. Insel has severely scolded his fellow psychiatrists in a national medical forum. Just to add a bit of fuel to the debate, the first comment on Dr. Carlat's blog posting is from Dr. Insel himself, who disputes many of Dr. Carroll's facts regarding the close ties Insel allegedly had with Dr. Nemeroff.

So I read the Commentary in JAMA carefully to try to figure out whom I agreed with, and find myself in this instance backing Dr. Carlat's general take on the matter. I can see how Drs. Carroll and Carlat came to such different conclusions because the Commentary is strangely composed, and actually seems to be two commentaries published side by side. One, as Dr. Carroll states, is largely a defense of psychiatry against charges that its practitioners are of lower moral caliber than other specialists. The second, as Dr. Carlat correctly points out, is an attack on his specialty for allowing industry money to distract it from science and quality patient care. Dr. Insel focuses mostly on the many non-drug treatments for mental illness, which have been scientifically proven, and yet remain largely underused and in some cases unreimbursed due to psychiatry's love affair with medications.

Perhaps Dr. Insel made a calculation that he needed to include his first commentary, making excuses for psychiatrists, as a sort of sugar coating on the bitterer pill of his second commentary. If so, he may have miscalculated as mostly he just confuses the reader as to what his main point is. I'll hope that the "real" Dr. Insel is the guy who wrote: "[A]cademic leaders and their professional societies will need to transform what has become a culture of influence. The greatest threat to an era of improved public health stemming from the productive and ethically sound relationship among academia, industry, and practice is a defiant embrace of the status quo..."

Insel TR. Psychiatrists' relationships with pharmaceutical companies: part of the problem or part of the solution? [commentary] JAMA 303:1192-93, Mar. 24/31, 2010.


Bernard Carroll said...

Howard, I appreciate your thoughts. Just for the record, here is my reply to Dr. Insel's challenge that appeared on Danny Carlat's site. My reply should go up there some time today.

In reply to Thomas Insel: Please do not be disingenuous. Dr. Nemeroff was your primary department chair and he played an essential role in bringing you to Emory University. You do not dispute that Dr. Nemeroff lobbied for your appointment as Director of NIMH. And I do recall seeing an announcement or press release about Dr. Nemeroff’s advisory role soon after your tenure began as Director of NIMH. Perhaps your aides can surface it.

Barney Carroll.

Bimatoprost said...

Bernard is right..your thoughts are really awesome and wonderful...
I am impressed..

Thanks for sharing
Generic Viagra, Kamagra Online

Sadness Addicted said...

Antidepressant advertising is directly targeted at manipulating normal healthy women to want to be medicated. Women must stand up to big pharma’s bullying them to over-medicate with antidepressants washing out their emotions & personalities and interfering being mothers, sisters, brothers, daughters, partners and lovers.. Women are targeted for antidepressants by big Pharma in the same way that tobacco companies targeted us 70 years ago. Drug companies are so effective at selling unhappiness to women that women take more than twice as many antidepressants as men.Like effexor Wyeth/Pfizer plans on using modern marketing techniques and direct payments to doctors to have Pristiq over prescribed instead of used based on evidence based diagnosis.